Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Recruiting · NCT06643819 · Interventional (participants receive a specific treatment) · Lead sponsor: Chong Kun Dang Pharmaceutical
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants who are 19 years old or older.
- Participants who have voluntarily decided to participate in this clinical trial and signed ICF.
Exclusion criteria
- Participants with a history of secondary hypertension or suspected secondary hypertension.
- Participants with a orthostatic hypotension.
- Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period.
- Participants with type 1 diabetes or poorly controlled diabetes.
- Participants who treated other clinical trial drugs within 4 weeks of screening visit.
- Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
- Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
- Participants who are unable to participate in this clinical trial at the discretion of the investigator.
Where it is running
1 location listed.
- Wonju Severance Christian Hospital - Wŏnju, South Korea